FDA Approves Bimzelx (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa
Key Insights
The FDA has approved Bimzelx (bimekizumab-bkzx) as the first and only interleukin-17F and -17A inhibitor for treating moderate to severe hidradenitis suppurativa (search) in adults.
Approval was based on the BE HEARD trials, demonstrating Bimzelx's efficacy and safety in improving hidradenitis suppurativa (search) signs and symptoms, with sustained outcomes through 48 weeks.
In clinical trials, a significantly higher proportion of patients treated with Bimzelx achieved a 50% or greater improvement in Hidradenitis Suppurativa (search) Clinical Response compared to placebo at week 16.
The U.S. Food and Drug Administration (FDA) has approved Bimzelx (bimekizumab-bkzx) for the treatment of moderate to severe hidradenitis suppurativa (search) (HS) in adults, marking a significant advancement in the treatment landscape for this chronic inflammatory skin condition. Developed by UCB (search), Bimzelx is the first and only approved interleukin-17F (IL-17F (search)) and interleukin-17A (IL-17A) inhibitor for this indication. The approval is based on data from the pivotal BE HEARD trials, which demonstrated the drug's efficacy and safety in improving the signs and symptoms of HS.
The BE HEARD trials, both Phase 3 studies, evaluated the efficacy and safety of Bimzelx in adult patients with moderate to severe HS. The primary endpoint was the proportion of patients achieving at least a 50% reduction from baseline in the Hidradenitis Suppurativa (search) Clinical Response (HiSCR50) at week 16. Key secondary endpoints included the proportion of patients achieving HiSCR75, indicating a 75% reduction in HS signs and symptoms.
Clinical Trial Results
Data from the BE HEARD trials showed a statistically significant improvement in HiSCR50 rates among patients treated with Bimzelx compared to placebo at week 16. Furthermore, a greater proportion of patients on Bimzelx also achieved HiSCR75 compared to those on placebo within the same timeframe. The treatment benefits were sustained through week 48, underscoring the long-term efficacy of Bimzelx.
According to Christopher Sayed, MD, professor of dermatology at the University of North Carolina at Chapel Hill and an investigator in the BE HEARD trials, less than half of patients are satisfied with currently FDA-approved treatments for HS. He noted that Bimzelx could be a preferred first-line therapy for most patients, given the strength of the efficacy data, particularly at weeks 48 and 96.
Mechanism of Action and Unmet Need
Bimzelx's unique mechanism of action, targeting both IL-17A and IL-17F (search), sets it apart from other biologics approved for HS. IL-17F is a key cytokine implicated in the pathogenesis of HS, with overexpression observed in affected tissues. By inhibiting both IL-17A and IL-17F, Bimzelx offers a more comprehensive approach to managing the inflammatory pathways driving HS.
Prior to this approval, treatment options for HS included antibiotics, retinoids, steroids, surgery, hormonal therapies, and other biologics. However, these treatments may not be effective for all patients, highlighting the need for additional therapeutic options. The approval of Bimzelx addresses this unmet need by providing a novel treatment that targets key cytokines involved in the disease process.
Safety Profile
The safety profile of Bimzelx in the BE HEARD trials was consistent with previous studies, with no new safety signals identified. Common adverse events included upper respiratory infections, oral candidiasis, and headache. The prescribing information includes warnings and precautions regarding potential risks, such as infections and hypersensitivity reactions.
With the FDA's approval, Bimzelx represents a significant advancement in the treatment of moderate to severe hidradenitis suppurativa (search), offering a new and effective option for patients who have not responded adequately to existing therapies.